Pattern of Buprenorphine Treatment Retention Among Youth Aged 10 to 18 Years-US, 2015 to 2021

JAMA Pediatr. 2024 Sep 1;178(9):940-942. doi: 10.1001/jamapediatrics.2024.2502.

Authors

Sarah Connolly¹, Andrew Terranella², Gery P Guy Jr², Christina A Mikosz²

Affiliations

¹ Epidemic Intelligence Service, Division of Overdose Prevention, US Centers for Disease Control and Prevention, Atlanta, Georgia.
² Division of Overdose Prevention, National Center for Injury Prevention and Control, US Centers for Disease Control and Prevention, Atlanta, Georgia.

PMID: 39073795
PMCID: PMC11287438 (available on 2025-07-29)
DOI: 10.1001/jamapediatrics.2024.2502

No abstract available

Plain language summary

This cohort study investigates patterns of buprenorphine treatment retention among US youth aged 10 to 18 years from 2015 to 2021.

MeSH terms

Adolescent
Analgesics, Opioid / therapeutic use
Buprenorphine* / therapeutic use
Child
Female
Humans
Male
Narcotic Antagonists / therapeutic use
Opiate Substitution Treatment / methods
Opioid-Related Disorders* / drug therapy
Retention in Care / statistics & numerical data
United States

Substances

Buprenorphine
Narcotic Antagonists
Analgesics, Opioid